The study found subtypes aligned by likelihood to be obese, to have cancer or heart disease, or to have mental illness.
Type 2 diabetes (T2D) behaves differently from patient to patient. But now, a team of researchers from the Icahn School of Medicine at Mount Sinai Hospital in New York has brought more clarity to this concept, with data that show T2D patients fall into 3 distinct groups.
The study, appearing in Science Translational Medicine, embraces the goals of President Obama’s precision medicine initiative by assembling data from electronic medical records (EMR) and genotype data from 2500 people with T2D who were treated at Mount Sinai.
All patients with T2D have diminished ability to use insulin efficiently, or no ability at all. This occurs for a variety of reasons, is associated with obesity and lack of exercise. While the risk of developing T2D increases with age, more young people are being diagnosed. Some patients are more likely than others to have comorbidities or develop disabling complications. Understanding which ones face the greatest risk could help physicians target these patients for closer monitoring and intervention.
By evaluating both the genetic information, health status, and other data points, the researchers were able to link patients to other similar patients, and eventually put patients into clusters. As this process progressed, 3 distinct subtypes emerged. According to the abstract, the Mount Sinai team identified more than 300 single nucleotide polymorphisms that were specific to each subtype.
The 3 groups were:
· Subtype 1 patients were younger, with higher risk of obesity, kidney disease, and retina problems that can progress to blindness. This group had lower white blood cell counts.
· Subtype 2 patients had lower body mass index (BMI) than the group overall, but more risk of developing cancer or heart disease.
· Subtype 3 patients had a high risk of heart disease as well, but also a high risk of mental illness and allergies.
The researchers called for more work with larger groups of patients to confirm their findings—and to figure out why these subtypes form.
“These distinctions might call for tailored treatment regimens rather than a one-size-fits-all approach for T2D,” the authors wrote. “Although a larger sample size is needed to determine causal relationships, this study demonstrates the potential of precision medicine.”
Reference
Li L, Cheng WY, Glicksberg BS, et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity [published online October 28, 2015]. Sci Transl Med. 2015; doi:10.1126/scitranslmed.aaa9364.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More